The inhibition of Nek6 function sensitizes human cancer cells to premature senescence upon serum reduction or anticancer drug treatment

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 175-182

  Jee, Hye Jin ^a   Kim, Hyun Ju ^a   Kim, Ae Jeong ^a   Song, Naree ^a   Kim, Minjee ^a   Lee, Hye Jeong ^a   Yun, Jeanho ^a  

^a Dong A University   (South Korea)

Author keywords

Cell cycle; Nek6; Premature senescence; ROS; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOXORUBICIN; NEK6 PROTEIN; NEK6KM PROTEIN; PROTEIN P53; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL AGING; CELL DEATH; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEK6 GENE; NONHUMAN; P53 GENE; PREMATURE AGING; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL AGING; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; CYCLIN B; DOXORUBICIN; G2 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; GENES, DOMINANT; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MUTANT PROTEINS; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; TUMOR BURDEN;

EID: 84878469193     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.012     Document Type: Article

References (25)

1. Gewirtz D.A., Holt S.E., Elmore L.W. Accelerated senescence. an emerging role in tumor cell response to chemotherapy and radiation. Biochem. Pharmacol. 2008, 76:947-957.
2. Ewald J.A., Desotelle J.A., Wilding G., Jarrard D.F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 2010, 102:1536-1546.
3. Roberson R.S., Kussick S.J., Vallieres E., Chen S.Y., Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005, 65:2795-2803.
4. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62:1876-1883.
5. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
6. Ben-Porath I., Weinberg R.A. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 2005, 37:961-976.
7. Schmitt C.A. Cellular senescence and cancer treatment. Biochim. Biophys. Acta 2007, 1775:5-20.
8. Campisi J., d'Adda di Fagagna F. Cellular senescence. when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8:729-740.
9. Jee H.J., Kim A.J., Song N., Kim H.J., Kim M., Koh H., Yun J. Nek6 overexpression antagonizes p53-induced senescence in human cancer cells. Cell Cycle 2010, 9:85-92.
10. Jee H.J., Kim H.J., Kim A.J., Song N., Kim M., Yun J. Nek6 suppresses the premature senescence of human cancer cells induced by camptothecin and doxorubicin treatment. Biochem. Biophys. Res. Commun. 2011, 408:669-673.
11. Jeon Y.J., Lee K.Y., Cho Y.Y., Pugliese A., Kim H.G., Jeong C.H., Bode A.M., Dong Z. Role of NEK6 in tumor promoter-induced transformation in JB6 C141 mouse skin epidermal cells. J. Biol. Chem. 2010, 285:28126-28133.
12. Nassirpour R., Shao L., Flanagan P., Abrams T., Jallal B., Smeal T., Yin M.J. Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target. Mol. Cancer Res. 2010, 8:717-728.
13. Takeno A., Takemasa I., Doki Y., Yamasaki M., Miyata H., Takiguchi S., Fujiwara Y., Matsubara K., Monden M. Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br. J. Cancer 2008, 99:1307-1315.
14. Chen J., Li L., Zhang Y., Yang H., Wei Y., Zhang L., Liu X., Yu L. Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem. Biophys. Res. Commun. 2006, 341:1059-1065.
15. Hashimoto Y., Akita H., Hibino M., Kohri K., Nakanishi M. Identification and characterization of Nek6 protein kinase, a potential human homolog of NIMA histone H3 kinase. Biochem. Biophys. Res. Commun. 2002, 293:753-758.
16. Yin M.J., Shao L., Voehringer D., Smeal T., Jallal B. The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J. Biol. Chem. 2003, 278:52454-52460.
17. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
18. Kim M.A., Kim H.J., Brown A.L., Lee M.Y., Bae Y.S., Park J.I., Kwak J.Y., Chung J.H., Yun J. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif. Exp. Mol. Med. 2007, 39:205-212.
19. O'Regan L., Blot J., Fry A.M. Mitotic regulation by NIMA-related kinases. Cell Div 2007, 2:25.
20. Belham C., Roig J., Caldwell J.A., Aoyama Y., Kemp B.E., Comb M., Avruch J. A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J. Biol. Chem. 2003, 278:34897-34909.
21. Lee M.Y., Kim H.J., Kim M.A., Jee H.J., Kim A.J., Bae Y.S., Park J.I., Chung J.H., Yun J. Nek6 is involved in G2/M phase cell cycle arrest through DNA damage-induced phosphorylation. Cell cycle 2008, 7:2705-2709.
22. O'Regan L., Fry A.M. The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 2009, 29:3975-3990.
23. Fry A.M. A role for Nek6 kinase activity in preventing senescence. Cell Cycle 2011, 10:19-20.
24. Yin M.J. Linking Nek6 to p53-induced senescence. Cell Cycle 2011, 10:18.
25. Johnston P.A., Grandis J.R. STAT3 signaling: anticancer strategies and challenges. Mol. Interv. 2011, 11:18-26.